Could a diabetes pill help teens with fatty liver? new trial aims to find out.
NCT ID NCT03867487
First seen Jan 22, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study tests whether a type 2 diabetes medicine (SGLT2 inhibitor) can safely reduce liver fat in adolescents aged 12-20 who have obesity and non-alcoholic fatty liver disease (NAFLD). About 40 participants will receive either the drug or a placebo for a set period. The main goal is to see if the drug lowers liver fat measured by MRI, while also checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, 60601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.